NW Bio reports positive top-line results from phase 3 glioblastoma trial

Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, reported November 17 that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma.